NeoGenomics: Rachel Stahler
NeoGenomics announced Rachel Stahler would join the company's board of directors, effective immediately. She will serve on the board's audit committee. Stahler was recently named the chief information officer for Merck's intended women's health and biosimilars spinoff Organon & Co. Previously, she was the CIO at pharmaceuticals firm Allergan, Syneos Health, and Optimer Pharmaceuticals.